Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (81-90 of 204) with videos related to

Pageof 21
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic OutcomesTawanda Gumbo, Jotam G Pasipanodya, Klaus Romero, et al.
Journal of Global Antimicrobial Resistance|January 28, 2021
Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system modelShashikant Srivastava, Moti Chapagain, Johanna van Zyl, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2015
Reply to "breakpoints and drug exposure are inevitably closely linked"Tawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
The Journal of Infectious Diseases|March 10, 2010
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutolShashikant Srivastava, Sandirai Musuka, Carleton Sherman, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium diseaseDevyani Deshpande, Shashikant Srivastava, Jotam G Pasipanodya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: GoldilocksShashikant Srivastava, Devyani Deshpande, Jotam Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourthsRonald G Hall, Mark A Swancutt, Claudia Meek, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex diseaseDevyani Deshpande, Shashikant Srivastava, Jotam G Pasipanodya, et al.
International Journal of Cardiology. Heart & Vasculature|April 10, 2019
Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot studyJustin Shenje, Tawanda Gumbo, Lubbe Wiesner, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Novel regimens for treatment of <i>Mycobacterium avium</i> lung disease based on advanced <i>in vitro</i> systems and the mathematics of basis functionsShashikant Srivastava, Sanjay Singh, Gunavanthi D Boorgula, et al.
Pageof 21

Showing results (81-90 of 204) with videos related to

Sort By:
Pageof 21
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2015
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic OutcomesTawanda Gumbo, Jotam G Pasipanodya, Klaus Romero, et al.
Journal of Global Antimicrobial Resistance|January 28, 2021
Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system modelShashikant Srivastava, Moti Chapagain, Johanna van Zyl, et al.
Antimicrobial Agents and Chemotherapy|January 29, 2015
Reply to "breakpoints and drug exposure are inevitably closely linked"Tawanda Gumbo, Jotam G Pasipanodya, Peter Wash, et al.
The Journal of Infectious Diseases|March 10, 2010
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutolShashikant Srivastava, Sandirai Musuka, Carleton Sherman, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium diseaseDevyani Deshpande, Shashikant Srivastava, Jotam G Pasipanodya, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2016
Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: GoldilocksShashikant Srivastava, Devyani Deshpande, Jotam Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourthsRonald G Hall, Mark A Swancutt, Claudia Meek, et al.
The Journal of Antimicrobial Chemotherapy|September 20, 2017
Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex diseaseDevyani Deshpande, Shashikant Srivastava, Jotam G Pasipanodya, et al.
International Journal of Cardiology. Heart & Vasculature|April 10, 2019
Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot studyJustin Shenje, Tawanda Gumbo, Lubbe Wiesner, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Novel regimens for treatment of <i>Mycobacterium avium</i> lung disease based on advanced <i>in vitro</i> systems and the mathematics of basis functionsShashikant Srivastava, Sanjay Singh, Gunavanthi D Boorgula, et al.
Pageof 21